1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

Description

This is a first-in-human study, Phase 1, randomized, placebo-controlled, double blinded study that will be conducted in 2 parts.

Conditions

Healthy

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a first-in-human study, Phase 1, randomized, placebo-controlled, double blinded study that will be conducted in 2 parts.

A Phase 1a/1b Study of OPT101 in Healthy Volunteers

1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

Condition
Healthy
Intervention / Treatment

-

Contacts and Locations

Centennial

IMMUNOe Research, Centennial, Colorado, United States, 80112

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to 55 Years

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    Yes

    Collaborators and Investigators

    Op-T LLC,

    Isaac Melamed, MD, PRINCIPAL_INVESTIGATOR, IMMUNOe Health Centers

    Study Record Dates

    2024-06-30